New combo therapy shows promise for rare blood cancer
Disease control
Ongoing
This phase II trial is testing whether combining venetoclax and azacitidine can help people with therapy-related myelodysplastic syndrome (t-MDS), a blood cancer that develops after prior cancer treatment. The study will enroll 33 adults and measure how many achieve complete remi…
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC